These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 22666496)

  • 61. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.
    LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease)
    Lancet; 2002 Apr; 359(9315):1379-87. PubMed ID: 11978335
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Incident venous thromboembolic events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).
    Freeman DJ; Robertson M; Brown EA; Rumley A; Tobias ES; Frölich M; Slagboom PE; Jukema JW; de Craen AJ; Sattar N; Ford I; Gaw A; Greer IA; Lowe GD; Stott DJ
    BMC Geriatr; 2011 Feb; 11():8. PubMed ID: 21342490
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease.
    Haria M; McTavish D
    Drugs; 1997 Feb; 53(2):299-336. PubMed ID: 9028747
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.
    Shepherd J; Blauw GJ; Murphy MB; Bollen EL; Buckley BM; Cobbe SM; Ford I; Gaw A; Hyland M; Jukema JW; Kamper AM; Macfarlane PW; Meinders AE; Norrie J; Packard CJ; Perry IJ; Stott DJ; Sweeney BJ; Twomey C; Westendorp RG;
    Lancet; 2002 Nov; 360(9346):1623-30. PubMed ID: 12457784
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The pravastatin inflammation CRP evaluation (PRINCE): rationale and design.
    Albert MA; Staggers J; Chew P; Ridker PM;
    Am Heart J; 2001 Jun; 141(6):893-8. PubMed ID: 11376301
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial.
    Lewis SJ; Sacks FM; Mitchell JS; East C; Glasser S; Kell S; Letterer R; Limacher M; Moye LA; Rouleau JL; Pfeffer MA; Braunwald E
    J Am Coll Cardiol; 1998 Jul; 32(1):140-6. PubMed ID: 9669262
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Long-term follow-up of the West of Scotland Coronary Prevention Study.
    Ford I; Murray H; Packard CJ; Shepherd J; Macfarlane PW; Cobbe SM;
    N Engl J Med; 2007 Oct; 357(15):1477-86. PubMed ID: 17928595
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The effects of pravastatin on hospital admission in hypercholesterolemic middle-aged men: West of Scotland Coronary Prevention Study.
    J Am Coll Cardiol; 1999 Mar; 33(4):909-15. PubMed ID: 10091815
    [TBL] [Abstract][Full Text] [Related]  

  • 69. C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).
    Sattar N; Murray HM; McConnachie A; Blauw GJ; Bollen EL; Buckley BM; Cobbe SM; Ford I; Gaw A; Hyland M; Jukema JW; Kamper AM; Macfarlane PW; Murphy MB; Packard CJ; Perry IJ; Stott DJ; Sweeney BJ; Twomey C; Westendorp RG; Shepherd J;
    Circulation; 2007 Feb; 115(8):981-9. PubMed ID: 17283264
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The effect of low-dose pravastatin in metabolic syndrome for primary prevention of cardiovascular disease in Japan: a post hoc analysis of the MEGA study.
    Matsushima T; Nakaya N; Mizuno K; Ohashi Y; Teramoto T; Yokoyama S; Ichikawa S; Ishikura N; Kamiyama K; Nakamura H;
    J Cardiovasc Pharmacol Ther; 2012 Jun; 17(2):153-8. PubMed ID: 22573644
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a).
    Deshmukh HA; Colhoun HM; Johnson T; McKeigue PM; Betteridge DJ; Durrington PN; Fuller JH; Livingstone S; Charlton-Menys V; Neil A; Poulter N; Sever P; Shields DC; Stanton AV; Chatterjee A; Hyde C; Calle RA; DeMicco DA; Trompet S; Postmus I; Ford I; Jukema JW; Caulfield M; Hitman GA
    J Lipid Res; 2012 May; 53(5):1000-1011. PubMed ID: 22368281
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Association of contemporary sensitive troponin I levels at baseline and change at 1 year with long-term coronary events following myocardial infarction or unstable angina: results from the LIPID Study (Long-Term Intervention With Pravastatin in Ischaemic Disease).
    White HD; Tonkin A; Simes J; Stewart R; Mann K; Thompson P; Colquhoun D; West M; Nestel P; Sullivan D; Keech AC; Hunt D; Blankenberg S;
    J Am Coll Cardiol; 2014 Feb; 63(4):345-54. PubMed ID: 24140630
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
    Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
    N Engl J Med; 1998 Nov; 339(19):1349-57. PubMed ID: 9841303
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.
    Schaefer EJ; McNamara JR; Tayler T; Daly JA; Gleason JL; Seman LJ; Ferrari A; Rubenstein JJ
    Am J Cardiol; 2004 Jan; 93(1):31-9. PubMed ID: 14697462
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Statin therapy of individuals with high risk for coronary disease].
    Holme I
    Tidsskr Nor Laegeforen; 1996 May; 116(12):1479-81. PubMed ID: 8650638
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.
    Shepherd J; Cobbe SM; Ford I; Isles CG; Lorimer AR; MacFarlane PW; McKillop JH; Packard CJ
    N Engl J Med; 1995 Nov; 333(20):1301-7. PubMed ID: 7566020
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A coronary primary prevention study of Scottish men aged 45-64 years: trial design. The West of Scotland Coronary Prevention Study Group.
    J Clin Epidemiol; 1992 Aug; 45(8):849-60. PubMed ID: 1624967
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study.
    Albert MA; Danielson E; Rifai N; Ridker PM;
    JAMA; 2001 Jul; 286(1):64-70. PubMed ID: 11434828
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER).
    Packard CJ; Ford I; Robertson M; Shepherd J; Blauw GJ; Murphy MB; Bollen EL; Buckley BM; Cobbe SM; Gaw A; Hyland M; Jukema JW; Kamper AM; Macfarlane PW; Perry IJ; Stott DJ; Sweeney BJ; Twomey C; Westendorp RG;
    Circulation; 2005 Nov; 112(20):3058-65. PubMed ID: 16275871
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Statins: new data in secondary prevention and diabetes. Pravastatin and simvastatin are the best-assessed statins.
    Prescrire Int; 2003 Aug; 12(66):143-8. PubMed ID: 12908497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.